CLEVELAND, OH – January 17, 2017
SapVax will develop a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology for immuno-oncology applications. It was formed by BioMotiv and UniServices, the commercialization company for the University of Auckland, New Zealand.
SapVax’s pipeline includes vaccines targeting the cancer antigen NY-ESO-1, expressed in a broad range of cancers, and Epstein-Barr virus proteins strongly associated with certain cancers, including lymphoma, nasopharyngeal cancer, and gastric cancer.
The company is based on intellectual property licensed from the University of Auckland and developed by Distinguished Professor Margaret Brimble and Doctor Geoff Williams in the School of Chemical Sciences, and Professor Rod Dunbar, a physician-scientist, in the School of Biological Sciences.